The expression level of estrogen and progesterone receptors is well correlated with breast cancer prognosis, while approximately 10-15% of breast cancer patients lack both hormone receptors and human epidermal growth factor receptor 2 (HER2), and this breast cancer is classified as triple-negative breast cancer. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.